糖尿病合并肾功能减退但无白蛋白尿的CKD进展至ESKD风险:CRIC研究
该多中心前瞻性队列研究纳入1908例糖尿病合并GFR降低的CRIC研究参与者,按尿白蛋白排泄水平分组,评估ESKD发生、CKD进展及eGFR下降速率。结果显示基线无或轻度白蛋白尿者占28%,但其进展至ESKD的风险远低于中重度白蛋白尿者,eGFR年下降速率也较慢。
要点
- 糖尿病合并GFR降低者中,28%基线无或仅轻度白蛋白尿,进展至ESKD比例仅5%。
- 白蛋白尿程度越高,ESKD、CKD进展风险及eGFR下降速率均显著增加。
- 无白蛋白尿的CKD患者eGFR下降速率与普通糖尿病人群相似。
核心结论
- 在糖尿病合并eGFR降低的人群中,无白蛋白尿或蛋白尿常见,且其ESKD、CKD进展或eGFR快速下降的风险远低于有白蛋白尿或蛋白尿者。
- 正常白蛋白尿CKD的eGFR下降速率与普通糖尿病人群相似。
研究设计与样本
- 多中心前瞻性队列研究,纳入美国CRIC研究中1908例糖尿病合并GFR降低的参与者。
- 预测因素为尿白蛋白和蛋白排泄量;结局为 incident ESKD、CKD进展(ESKD或eGFR较基线下降≥50%)及肾功能年下降速率。
主要发现
- 基线平均eGFR为41.2mL/min/1.73m2;28%参与者24小时尿白蛋白排泄正常或轻度增加(<30mg/d),但在进展至ESKD者中仅占5%。
- 基线尿白蛋白正常或轻度增加、中度增加(30-299mg/d)、重度增加(300-999mg/d和≥1,000mg/d)组的ESKD粗发生率分别为7.4、34.8、78.7和178.7/1000人年。
- 上述四组的CKD进展率分别为17.0、61.4、130.5和295.1/1000人年;eGFR年下降速率分别为-0.17、-1.35、-2.74和-4.69mL/min/1.73m2。
临床怎么用
- 对于糖尿病合并GFR降低的患者,应重视白蛋白尿/蛋白尿的评估以进行风险分层。
- 无白蛋白尿的CKD患者ESKD风险较低,但仍需监测肾功能下降。
局限性
- 无法与健康对照进行比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Reduced glomerular filtration rate (GFR) in the absence of albuminuria is a common manifestation of chronic kidney disease (CKD) in diabetes. However, the frequency with which it progresses to end-stage kidney disease (ESKD) is unknown. STUDY DESIGN: Multicenter prospective cohort study. SETTING & PARTICIPANTS: We included 1,908 participants with diabetes and reduced GFR enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study in the United States. PREDICTORS: Urinary albumin and protein excretion. OUTCOMES: Incident ESKD, CKD progression (ESKD or ≥50% reduction in estimated GFR [eGFR] from baseline), and annual rate of decline in kidney function. MEASUREMENTS: ESKD was ascertained by self-report and by linkage to the US Renal Data System. We used Cox proportional hazards modeling to estimate the association of albuminuria and proteinuria with incident ESKD or CKD progression and linear mixed-effects models to assess differences in eGFR slopes among those with and without albuminuria. RESULTS: Mean eGFR at baseline was 41.2mL/min/1.73m2. Normal or mildly increased 24-hour urinary albumin excretion (<30mg/d) at baseline was present in 28% of participants, but in only 5% of those progressing to ESKD. For those with baseline normal or mildly increased albuminuria, moderately increased albuminuria (albumin excretion, 30-299mg/d), and 2 levels of severely increased albuminuria (albumin excretion, 300-999 and ≥1,000mg/d): crude rates of ESKD were 7.4, 34.8, 78.7, and 178.7 per 1,000 person-years, respectively; CKD progression rates were 17.0, 61.4, 130.5, and 295.1 per 1,000 person-years, respectively; and annual rates of eGFR decline were -0.17, -1.35, -2.74, and -4.69mL/min/1.73m2, respectively. LIMITATIONS: We were unable to compare the results with healthy controls. CONCLUSIONS: In people with diabetes with reduced eGFRs, the absence of albuminuria or proteinuria is common and carries a much lower risk for ESKD, CKD progression, or rapid decline in eGFR compared with those with albuminuria or proteinuria. The rate of eGFR decline in normoalbuminuric CKD was similar to that reported for the general diabetic population.
引用
- Koye DN, Magliano DJ, Reid CM, et al. Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis. 2018. PMID: 29784612. doi:10.1053/j.ajkd.2018.02.364
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。